The global biotech industry was estimated to be USD73.12 billion in 2006 compared to USD63.3 billion in 2005 up by 15.49%. There is an increase in the global revenues from Canada and Europe regions which is the new cynosure for the global industry.The segments of the industry along with the major global players of the industry are also discussed with their profiles. This report also has details on mergers and acquisitions in the industry that happened in 2006 and to end the report a future outlook for the industry has also been given.

CONTENTS 1. Industry Overview 1.1 Industry growth 1.1.2 Industry concentric 1.1.3 Industry analysis 1.1.4 R&D expenditure 1.1.5 Number of players 1.1.6 Financial flow 1.2 References 2. Major Markets 2.1 Economy 2.2 Global market 2.3. North America 2.3.1 Biotechnology Industry 2.4 Europe 2.4.1 Biotechnology industry 2.5 Asia- Pacific region 2.5.1 Biotechnology Industry 2.6 References 3. Major Players 3.1 Introduction 3.2 Novartis 3.3 Amgen 3.4 Genentech 3.5 Genzyme 3.6 Gilead Sciences 3.7 Biogen Idec 3.8 MedImmune Inc 3.9 Invitrogen 3.10 Merck Serono 3.11 Millennium Pharmaceutical Inc 3.12 References 4. Mergers and Acquisitions 4.1 Introduction 4.2 Major Disclosed Deals 4.3 Undisclosed Deals 4.4 Some Major Deals 4.5 Trends in the deals 4.6 References 5. Outlook 5.1 References LIST OF FIGURES Figure 1.1: Biotech Industry Revenues, 2002-2006 Figure 1.2: Global Revenue Break-up, 2006 Figure 1.3: Global Biotech Industry Net loss, 2002-2006 Figure 1.4: Global R&D Expenditure, 2002-2006 Figure 1.5: Companies in Biotech Industry, 2002-2006 Figure 1.6: Biotech Financing, 2002-2006 Figure 2.1: Global Real GDP Growth (2005-06) Figure 2.2: Real GDP Growth Rate in the US (2005-06) Figure 2.3: Real GDP Growth Rate in Canada (2005-06) Figure 2.4: Real GDP Growth Rate in European Union (2005-06) Figure 2.5: Real GDP Growth Rate in Japan (2005-06) Figure 2.6: Real GDP Growth Rate in India (2005-06) Figure 2.7: Real GDP Growth Rate in China (2005-06) Figure 2.8: Major regions of Biotech Industry 2002- 2006 Figure 2.9: North American Biotech Revenue, 2002-2006 Figure 2.10: North American R&D Expenditure, 2002-2006 Figure 2.11: Biotech Companies in North America, 2002-2006 Figure 2.12: European Biotech Revenue, 2002-2006 Figure 2.13: Biotech Companies in Europe, 2002-2006 Figure 2.14: R&D Investment in Europe, 2002-2006 Figure 2.15: Biotech Revenue in Asia-Pacific, 2002-2006 Figure 2.16: Biotech Companies in Asia-Pacific, 2002-2006 Figure 2.17: R&D expenditure in Asia-Pacific, 2002-2006 LIST OF TABLESTable 1.1: Major IPOs during 2006 Table 1.2: Major venture financings during 2006 Table 1.3: Selected partnering transactions during 2006 Table 1.4: Major drugs approved by FDA during 2006 Table 1.5: Major biotech drugs in pipeline (2006) Table 1.6: Some important government R&D funding, 2006 Table 2.1: Major companies in North America Table 2.3: Major European Companies 2006 Table 3.1: Top 10 Biotechnology Companies, 2006 Table 3.2: Novartis 2005- 2006 Table 3.3: Amgen 2005- 2006 Table 3.4: Genentech 2005-2006 Table 3.5: Genzyme 2005-2006 Table 3.6: Gilead Sciences 2005-2006 Table 3.7: Biogen Idec 2005 – 2006 Table 3.8: MedImmune 2005 – 2006 Table 3.9: Invitrogen 2005-2006 Table 3.10: Merck Serono 2005- 2006 Table 3.11: Millennium 2005 – 2006 Table 4.1: Major deals announced/completed 2006 Table 4.2: Undisclosed deals 2006